Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2005 1
2006 1
2009 1
2010 1
2011 2
2012 2
2013 3
2014 5
2015 7
2016 13
2017 9
2018 6
2019 10
2020 13
2021 9
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C.
Zeng M, Xiong Y, Safaee N, Nowak RP, Donovan KA, Yuan CJ, Nabet B, Gero TW, Feru F, Li L, Gondi S, Ombelets LJ, Quan C, Jänne PA, Kostic M, Scott DA, Westover KD, Fischer ES, Gray NS. Zeng M, et al. Among authors: westover kd. Cell Chem Biol. 2020 Jan 16;27(1):19-31.e6. doi: 10.1016/j.chembiol.2019.12.006. Epub 2019 Dec 26. Cell Chem Biol. 2020. PMID: 31883964 Free article.
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Iyengar P, et al. Among authors: westover kd. JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11. JAMA Oncol. 2018. PMID: 28973074 Free PMC article. Clinical Trial.
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Vander Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM. Pacold ME, et al. Among authors: westover kd. Nat Chem Biol. 2016 Jun;12(6):452-8. doi: 10.1038/nchembio.2070. Epub 2016 Apr 25. Nat Chem Biol. 2016. PMID: 27110680 Free PMC article.
Rationale for RAS mutation-tailored therapies.
Montalvo SK, Li L, Westover KD. Montalvo SK, et al. Among authors: westover kd. Future Oncol. 2017 Feb;13(3):263-271. doi: 10.2217/fon-2016-0363. Epub 2016 Oct 12. Future Oncol. 2017. PMID: 27728979 Review.
The to and fro of Rho.
Westover KD. Westover KD. Structure. 2021 Jun 3;29(6):507-509. doi: 10.1016/j.str.2021.05.009. Structure. 2021. PMID: 34087169 Free PMC article.
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.
Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L, Ficarro SB, Meyer CJ, Sinha D, You I, Tse J, He Z, Ji W, Che J, Kim AY, Yu T, Wen K, Anderson KC, Marto JA, Westover KD, Zhang T, Gray NS. Lu W, et al. Among authors: westover kd. J Med Chem. 2023 Mar 9;66(5):3356-3371. doi: 10.1021/acs.jmedchem.2c01834. Epub 2023 Feb 24. J Med Chem. 2023. PMID: 36826833
Tissue-Specific Oncogenic Activity of KRASA146T.
Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Poulin EJ, et al. Among authors: westover kd. Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5. Cancer Discov. 2019. PMID: 30952657 Free PMC article.
85 results